Company intelligence / Profile preview

SynsorBio

Ownership: Private
Development stage: Commercial

Overview

SynsorBio is a leading Chinese company specializing in proprietary CRISPR-based diagnostic technologies. The company integrates advanced gene editing and molecular detection to deliver rapid and accurate diagnostic solutions. Specific clinical results are not detailed in public sources.

Modalities: CRISPR-based diagnosticsNucleic acid detection technology
Industry: Molecular Diagnostics

Drug pipeline

1 asset

CDetection.v2

Commercial

Indications: COVID-19 diagnostics

Beyond the preview

Go deeper on SynsorBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynsorBio.

Explore the full profile